Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

NeuroblastORG

Financiado

Developing neural crest organoids with inducible neuroblastoma to model chemores...

Developing neural crest organoids with inducible neuroblastoma to model chemoresistance in MYCN amplification related high-risk cases Neuroblastoma (NB) is the most common cancer in infants and the 3rd most common cancer in children. According to the WHO 90% of NBs occur in children younger than 5 years old and 15% of all pediatric cancer related death are due t... ver más

28/02/2025

HUN-REN RESEARCH C...

158K€

Presupuesto del proyecto: 158K€

Líder del proyecto

HUNREN TERMESZETTUDOMANYI KUTATOKOZPONT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-09-26

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-WIDERA-2022-TALENTS-02-01: Fostering balanced brain circulation – ERA Fellowships

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

HUN-REN RESEARCH CENTRE FOR...

157.62K€ | Lider

Proyectos interesantes

Decode Relapse Decoding and Targeting Treatment-Resistant Metastatic Neurob... 2M€ Cerrado

CancerHetero Dissection of tumor heterogeneity in vivo 2M€ Cerrado

CNS2023-143930 Biotecnología 195K€ Cerrado

SC-Plasticity Applying novel single-cell multiomics to elucidate leukaemia... 2M€ Cerrado

Sugarcoating matters Sugarcoating matters: Deciphering the effects of aberrant re... 188K€ Cerrado

PREDICT PREcision medicine Drug combination testing In neuroblastoma... 1M€ Cerrado

Últimas noticias

25-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 52 concesiones

25-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 1 concesiones

25-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 6 concesiones

Duración del proyecto: 29 meses Fecha Inicio: 2022-09-26
Fecha Fin: 2025-02-28

Líder del proyecto

HUNREN TERMESZETTUDOMANYI KUTATOKOZPONT

TRL 4-5

Presupuesto del proyecto 158K€

Descripción del proyecto Neuroblastoma (NB) is the most common cancer in infants and the 3rd most common cancer in children. According to the WHO 90% of NBs occur in children younger than 5 years old and 15% of all pediatric cancer related death are due to NB. Approximately 20% of NB cases are characterized by the amplification of the MYCN gene, which is linked to more aggressive tumors and poor prognosis (high-risk NB). Despite recent treatment advances, relapsing high-risk NB often leads to death. Understanding mechanisms of therapy resistance can help to develop more effective treatment protocols. However, investigation of acquired resistance upon chemotherapy is largely limited by the number of patients with high-risk NB and the availability of adequate model systems. Mice models of NB are often used, however species specific differences in sympathoblast development might result in misleading findings. Sympathoblast are the fetal counterparts of NB cancer cells and they are derived from the neural crest (NC). The overall aim of the NeuroblastORG project is to establish a human organoid model of the NC lineage, which can recapitulate human specific embryonic developmental stages, while also giving rise to sympathoblast-like NB cells, in addition to healthy sympathoadrenergic lineage derivatives (NB organoid). To reach this aim, human induced pluripotent stem cell lines will be genetically modified to overexpress the MYCN gene under the control of an NC-specific promoter, but only in a subset of NC cells within the organoids. Relevance of the established model will be validated by comparing gene expression signatures between NB organoids and human NB patient tumour samples. The NB organoid model system will provide a platform to simulate treatment of NB cells with NB-therapy relevant agents and monitor the effect of the applied treatment, allowing the investigation of human NB-specific chemoresistance acquisition in MYCN amplification related high-risk cases.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores